Great PR today. Succinct and straightforward. No
Post# of 72447
(Total Views: 399)
Posted On: 12/28/2017 11:00:49 AM
Great PR today. Succinct and straightforward. No need to waste effort fluffing it up because the content speaks for itself. IPIX is in an extremely good position right now with multiple drugs having completed multiple successful trials. Then there is the best paragraph of the PR:
My belief at this point is that IPIX is past the point of negotiating whether or not one or more of the multiple pharma companies want to enter into a deal. I think that it is down to the detailed money negotiations now. BP's have to analyze the trial results, perform their risk to cost/benefit figures, and make Leo their offers. Leo, Art, and Krishna have to decide how hard a bargain they are willing to drive before they run the risk of pricing themselves out of a deal.
Or maybe not. Maybe IPIX is content to continue to push further without partnership support. I dont believe that to be the case even though I think that IPIX has that option. I think that Leo is looking at the bigger picture of the B and K franchises and is willing to negotiate the first deal to a point that makes the BP's feel like they are getting a good price but sets up IPIX to have the ample funding needed to accelerate the entire company pipeline. He knows the end game is partly in Brilicidin but mostly in Kevetrin and it is going to take a lot more time and money to get there. IPIX will do what makes the most long term sense with their first deal.
Quote:
To advance our pipeline in an expeditious manner, this year we placed an emphasis on partnering—actively engaging global and regional pharmaceutical companies interested in licensing our novel drug candidates. These efforts have led to highly productive, mature (late-phase, ongoing) discussions, with multiple pharmaceutical companies, which we hope will bear fruit in the coming year.
My belief at this point is that IPIX is past the point of negotiating whether or not one or more of the multiple pharma companies want to enter into a deal. I think that it is down to the detailed money negotiations now. BP's have to analyze the trial results, perform their risk to cost/benefit figures, and make Leo their offers. Leo, Art, and Krishna have to decide how hard a bargain they are willing to drive before they run the risk of pricing themselves out of a deal.
Or maybe not. Maybe IPIX is content to continue to push further without partnership support. I dont believe that to be the case even though I think that IPIX has that option. I think that Leo is looking at the bigger picture of the B and K franchises and is willing to negotiate the first deal to a point that makes the BP's feel like they are getting a good price but sets up IPIX to have the ample funding needed to accelerate the entire company pipeline. He knows the end game is partly in Brilicidin but mostly in Kevetrin and it is going to take a lot more time and money to get there. IPIX will do what makes the most long term sense with their first deal.
(5)
(0)